Breast Cancer T Stage with Nipple Involvement
Breast cancer with nipple involvement alone does NOT automatically classify as T4b—the T stage is determined by the size and characteristics of the underlying parenchymal tumor, not by nipple involvement itself. 1
Key Classification Principle
According to ESMO guidelines, Paget's disease of the nipple (nipple involvement) is classified as Tis (Paget's) when NOT associated with invasive carcinoma or carcinoma in situ in the underlying breast parenchyma. When there IS an underlying invasive tumor in the breast parenchyma, the T stage is based entirely on the size and characteristics of that parenchymal disease, though the presence of Paget's disease should still be documented. 1
Staging Algorithm for Nipple Involvement
If Paget's Disease ONLY (no underlying invasive cancer):
- Classification: Tis (Paget's)
- This represents carcinoma in situ confined to the nipple
If Invasive Cancer Present in Breast Parenchyma:
Stage according to tumor size and extension:
- ≤20 mm = T1 (subdivided into T1mi, T1a, T1b, T1c based on exact size)
- >20 mm but ≤50 mm = T2
- >50 mm = T3
- Any size with chest wall extension and/or skin ulceration/nodules = T4
The nipple involvement itself does not upgrade the T stage—it is simply noted in the pathology report. 1
Critical Distinction: T4b vs Nipple Involvement
T4b requires skin ulceration, ipsilateral satellite nodules, or edema (peau d'orange) that does NOT meet criteria for inflammatory carcinoma. 1
- Simple nipple retraction or Paget's disease does NOT qualify as T4b
- Invasion of the dermis alone does NOT qualify as T4
- Dimpling, nipple retraction, or other skin changes may occur in T1, T2, or T3 without changing classification 2
Common Pitfall to Avoid
Do not automatically classify nipple involvement as T4b or advanced stage. The 2015 ESMO guidelines explicitly state that skin changes including nipple retraction may occur in T1, T2, or T3 tumors without upgrading the T classification. 2 Only when there is true skin ulceration, satellite nodules, or peau d'orange does the tumor become T4b.
Clinical Implications
Research demonstrates that grouping all skin-involved breast cancers as stage III regardless of size leads to inaccurate prognostication—5-year disease-specific survival varies dramatically from 95.8% for neostage I to 36.4% for neostage IIIC when skin involvement is present. 3 This reinforces that tumor size and nodal status should take precedence over skin/nipple involvement in determining T stage.